InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2023-02-27 | Daniel Goldman(D-NY10) | house | Sale | $1,001 - $15,000 |
No financial data available for NPPNY.
Company may not file with SEC or CIK is unresolved.
Nippon Shinyaku (TSE:4516): Exploring Valuation After Recent Share Price Fluctuations
Regenxbio Inc (RGNX) Q3 2025 Earnings Call Highlights: Strong Financial Position and Strategic ...
Ionis: What Upside Is Left After Shares Rocketed Higher Following Positive Trial Data?
Nippon Shinyaku Selects LifeSphere® Safety
Brogidirsen (NS-089/NCNP-02) 3.5 Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2025 World Muscle Society Congress
Buloxibutid Receives Orphan Drug Designation in Japan for the Treatment of Idiopathic Pulmonary Fibrosis
Nippon Shinyaku (TSE:4516): Valuation Insights as Fundamental Drivers Face Investor Scrutiny
FDA Grants Fast Track Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
5 Reasons To Buy Regenxbio Right Now
Capricor completes U.S. marketing submission for lead candidate
Week In Review: Nippon Shinyaku Signs $735m Deal For DMD Therapy